Answers are grounded in this paper and cite their sources.
Background. Pancreas transplantation remains among the few treatments able to restore sustained insulin independence in selected patients with type 1 diabetes mellitus, yet annual transplant numbers have declined across the Eurotransplant region. Previous work has linked center volume to posttransplant graft and patient survival, but its influence on access to transplantation and waiting list mortality remains incompletely characterized. Methods. We performed a retrospective cohort study of 6672 patients listed for vascularized pancreas transplantation within Eurotransplant between 2000 and 2024. Centers were classified each year by tertile of annual transplant volume into low-, medium-, and high-volume categories. Cumulative incidence functions for transplantation and waiting list mortality were estimated using the Aalen–Johansen estimator. Cause-specific time-varying Cox proportional hazards models were fitted, adjusting for recipient age, sex, blood group, country, registration year, and waiting list size. Results. Overall, 4410 patients (66.1%) received a transplant and 655 (9.8%) died on the waiting list. Compared with low-volume centers, listing at medium-volume (hazard ratio [HR], 1.13; 95% confidence interval [CI], 1.01-1.27) and high-volume centers (HR, 1.30; 95% CI, 1.16-1.45) was independently associated with a higher probability of transplantation. Waiting list mortality was also lower at medium-volume (HR, 0.70; 95% CI, 0.53-0.92) and high-volume centers (HR, 0.70; 95% CI, 0.55-0.90). Conclusions. Within Eurotransplant, patients listed at low-volume pancreas transplant centers face a dual disadvantage of reduced access to transplantation and higher waiting list mortality, with implications for allocation policy, center designation, and patient referral.
No takes yet. Share an insight, caveat, or question.
Filipe et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: